{"schema_version":"1.0","type":"article","title":"一篇文章講通現在的“禮來”併購邏輯","url":"https://drugnews.com.tw/articles/2026-04-29-dcard-261388300.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-29-dcard-261388300.md","lang":"zh-Hant","date":"2026-04-29","publish_at":"2026-04-29T10:30:00+08:00","updated_at":"2026-04-29","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","AI","GLP-1","自體免疫","BD","臨床數據"],"summary":"💡 四個月，五筆交易，若把交易上限全部加總，Eli Lilly 在 2026 年前四個月已經丟出超過 187 億美元的併購火力：1 月的 Ventyx Biosciences、2 月的 Orna Therapeutics、3 月的 Centessa Pharmaceuticals、4 月的 Cro…","key_points":[],"facts":[],"sections":["當現金多到必須花掉：Lilly 四個月五筆併購，買的不是資產，而是 GLP-1 之後的下一個十年","01｜先把話說白：Lilly 買的不是營收，而是估值延續權","02｜兩筆 in vivo CAR-T：Lilly 押注的不是改良版 CAR-T，而是重寫細胞療法經濟學","03｜78 億美元買睡眠：Lilly 在 Centessa 身上，買的是一個被低估太久的神經科學市場","04｜CrossBridge 不大，但很關鍵：Lilly 想買的是 ADC 的下一個版本","05｜把五筆交易拼起來看，Lilly 的併購地圖其實非常連貫"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/legal/transactional/eli-lilly-buy-ventyx-biosciences-12-billion-deal-2026-01-07/","source":"","date":"","url":"https://www.reuters.com/legal/transactional/eli-lilly-buy-ventyx-biosciences-12-billion-deal-2026-01-07/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"\"Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance","source":"Eli Lilly and Company\"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/markets/deals/pfizer-buy-seagen-deal-valued-43-billion-2023-03-13/","source":"","date":"","url":"https://www.reuters.com/markets/deals/pfizer-buy-seagen-deal-valued-43-billion-2023-03-13/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-weight-loss-pill-wins-us-approval-2026-04-01/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/lillys-weight-loss-pill-wins-us-approval-2026-04-01/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"www.sciencedirect.com","source":"","date":"","url":""},{"title":"https://www.sciencedirect.com/science/article/abs/pii/S2352302624002734","source":"","date":"","url":"https://www.sciencedirect.com/science/article/abs/pii/S2352302624002734"},{"title":"www.sciencedirect.com","source":"","date":"","url":""},{"title":"[6]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/legal/litigation/eli-lilly-advanced-talks-acquire-kelonia-therapeutics-over-2-billion-wsj-says-2026-04-19/","source":"","date":"","url":"https://www.reuters.com/legal/litigation/eli-lilly-advanced-talks-acquire-kelonia-therapeutics-over-2-billion-wsj-says-2026-04-19/"},{"title":"www.reuters.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：一篇文章講通現在的“禮來”併購邏輯（圖 1）","url":"https://drugnews.com.tw/assets/articles/dcard-261388300/dcard-01.webp"},{"alt":"Dcard 原圖：一篇文章講通現在的“禮來”併購邏輯（圖 2）","url":"https://drugnews.com.tw/assets/articles/dcard-261388300/dcard-02.webp"},{"alt":"Dcard 原圖：一篇文章講通現在的“禮來”併購邏輯（圖 3）","url":"https://drugnews.com.tw/assets/articles/dcard-261388300/dcard-03.png"},{"alt":"Dcard 原圖：一篇文章講通現在的“禮來”併購邏輯（圖 4）","url":"https://drugnews.com.tw/assets/articles/dcard-261388300/dcard-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/dcard-261388300/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-29）。一篇文章講通現在的“禮來”併購邏輯。https://drugnews.com.tw/articles/2026-04-29-dcard-261388300.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-29-dcard-261388300-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}